Table II.
Treatment protocols, cycle characteristics and pregnancy outcomes for 237 IVF cycles among 174 women.
| Cycle-specific characteristics | Among 237 IVF cycles, n (%) |
|---|---|
| IVF protocola | |
| Luteal phase | 143 (60) |
| LDLL | 135 (57) |
| RDLL | 8 (3) |
| Flare | 58 (25) |
| Antagonist | 35 (15) |
| Mean ± SD (range) | |
| Day 3 FSH (IU/l) | 7.1 ± 2.3 (0.2–15.2) |
| Peak E2 (pg/ml) | 2083 ± 902.1 (551–5263) |
| Oocytes retrieveda | 10.8 ± 5.3 (1–29) |
| Mature (MII) oocytes | 9.2 ± 4.5 (0–24) |
| Normal (2PN) fertilized oocytes | 6.5 ± 3.6 (0–21) |
| Mean (SD) | |
| Fertilization rate (2PN/MII oocytes)a | 0.71 (0.22) |
| Maturation rate (MII/oocytes retrieved)a | 0.87 (0.14) |
| Embryo-specific characteristics | Among 1449 embryos n (%) |
| Day 3 embryos (cleavage rate) | |
| No cleavage | 13 (1) |
| Slow (2–5 cells) | 426 (29) |
| Normal (6–8 cells) | 926 (64) |
| Accelerated (>8 cells) | 84 (6) |
| Day 3 embryo quality, among 1389 embryos | |
| Poor | 295 (21) |
| Intermediate | 322 (23) |
| High | 772 (56) |
| Blastocyst formation, among 1143 embryos | 361 (32) |
E2, estradiol; MII, metaphase II oocyte; LDLL, low-dose leuprolide lupron; RDLL, regular-dose leuprolide lupron.
a236 cycles; Owing to rounding, percentage totals may not sum to 100%.